FilingSEC EDGAR6-K
IceCure Medical Presents Positive Clinical Data for ProSense® at EUSOBI 2026
· SEC accepted
Stageclinical data presentation
Filing content
The company presented 12-month clinical results for its ProSense® breast cancer cryoablation at EUSOBI, reporting a 97.5% objective response rate for patients treated with cryoablation plus endocrine therapy.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…